0001104659-22-010998.txt : 20220202
0001104659-22-010998.hdr.sgml : 20220202
20220202190107
ACCESSION NUMBER: 0001104659-22-010998
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220131
FILED AS OF DATE: 20220202
DATE AS OF CHANGE: 20220202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GRAY WILLIAM GARRETT
CENTRAL INDEX KEY: 0001692961
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38128
FILM NUMBER: 22585454
MAIL ADDRESS:
STREET 1: 2 GANSEVOORT STREET,
STREET 2: 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Checkpoint Therapeutics, Inc.
CENTRAL INDEX KEY: 0001651407
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 472568632
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 GANSEVOORT STREET
STREET 2: 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
BUSINESS PHONE: 212-554-4366
MAIL ADDRESS:
STREET 1: 2 GANSEVOORT STREET
STREET 2: 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
4
1
tm225237-2_4.xml
FORM 4
X0306
4
2022-01-31
0
0001651407
Checkpoint Therapeutics, Inc.
CKPT
0001692961
GRAY WILLIAM GARRETT
95 SAWYER RD, SUITE 110
WALTHAM
MA
02453
0
1
0
0
Chief Financial Officer
COMMON STOCK (RESTRICTED)
2022-01-31
4
A
0
137000
0.00
A
619170
D
COMMON STOCK
2022-02-01
4
S
0
37063
2.508
D
582107
D
The shares of restricted stock vest as follows: one-fourth on January 31, 2023, one-fourth on January 31, 2024, one-fourth on January 31, 2025 and one-fourth on January 31, 2026
Includes shares of restricted Common Stock, which vest over various time periods
In connection with the vesting of 72,750 shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Gray's tax withholding obligations. Mr. Gray had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock.
Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $2.50 to $2.55. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
/s/ Garrett Gray
2022-02-02